Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zhangzhou Pientzehuang Pharmaceutical Co's quarterly Beginning Cash Position
declined
from Dec. 2025 (¥1,338 Mil) to Mar. 2026 (¥1,221 Mil) but then
increased
from Mar. 2026 (¥1,221 Mil) to Jun. 2026 (¥1,925 Mil).
Zhangzhou Pientzehuang Pharmaceutical Co's annual Beginning Cash Position
declined
from Dec. 2023 (¥2,412 Mil) to Dec. 2024 (¥1,077 Mil) but then
increased
from Dec. 2024 (¥1,077 Mil) to Dec. 2025 (¥1,483 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhangzhou Pientzehuang Pharmaceutical Co Beginning Cash Position Chart
Zhangzhou Pientzehuang Pharmaceutical Co Annual Data
What does a Beginning Cash Position of ¥1,925 Mil mean?
Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) has a Beginning Cash Position of ¥1,925 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors.
Is Zhangzhou Pientzehuang Pharmaceutical Co's Beginning Cash Position too high?
Zhangzhou Pientzehuang Pharmaceutical Co's current Beginning Cash Position is ¥1,925 Mil. Overall, Zhangzhou Pientzehuang Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhangzhou Pientzehuang Pharmaceutical Co's Beginning Cash Position compare to LLY and JNJ?
Zhangzhou Pientzehuang Pharmaceutical Co's Beginning Cash Position of ¥1,925 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Zhangzhou Pientzehuang Pharmaceutical Co and its competitors. Zhangzhou Pientzehuang Pharmaceutical Co's current Beginning Cash Position is ¥1,925 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhangzhou Pientzehuang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥174.53, compared to a current price of ¥123.57 — trading 29.2% below its estimated fair value. The current Beginning Cash Position is ¥1,925 Mil. Zhangzhou Pientzehuang Pharmaceutical Co's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436), the current Beginning Cash Position is ¥1,925 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhangzhou Pientzehuang Pharmaceutical Co (SHSE:600436) Overvalued in 2026?
Based on GuruFocus' analysis, Zhangzhou Pientzehuang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥123.57 is trading 29.2% below its estimated GF Value™ of ¥174.53.
GuruFocus considers Zhangzhou Pientzehuang Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600436:
Beginning Cash Position: ¥1,925 Mil
GF Value™: ¥174.53 vs. price of ¥123.57 (29.2% below fair value)
No single metric tells the full story. See the SHSE:600436 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhangzhou Pientzehuang Pharmaceutical Co Ltd produces and sells Chinese medicines. The company's product categories include tablets, hard capsules, granules, pills (water pills, honey pills), syrups, tinctures (including external use), ointments, lozenges, decoctions, Chinese herbal medicine slices (including direct oral slices) (clean preparation); production of candy products (candy), health food products; and production of beverages (solid beverages).
86GF Score
Get the complete analysis for SHSE:600436
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600436 has been successfully added to your 
